Abstract
Permanent implant prostate brachytherapy first gained popularity in the 1970s but subsequently underwent more than a 10-year period of near abandonment. Loss of interest in the technique stemmed from technical limitations of the retropubic approach that often resulted in poor physical distribution of the implanted seeds. This, together with inappropriately chosen patients, often led to poor long-term results and a loss of enthusiasm for the technique. Improving external beam and surgical techniques also contributed to this shift in emphasis.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Locke J, Ellis W, Wallner K, et al.: Risk factors for acute urinary retention requiring 16. temporary intermittent catheterization after prostate brachytherapy: a prospective study. Intl Radiat Oncol Biol Phys 2002, 52: 712–719.
Terk MD, Stock RG, Stone NN: Identification of patients at increased risk for 17. prolonged urinary retention following radioactive seed implantation of the prostate. J Urol 1998, 160: 1379–1382.
Wallner K, Smathers S, Sutlief S, et al.: Prostate brachytherapy in patients with median lobe hyperplasia. Int J Cancer 2000, 90:152–156. 18.
Blasko JC, Ragde H, Grimm PD: Transperineal ultrasound-guided implantation of the prostate: morbidity and complications. Scand J Urol Nephrol Suppl 1991, 137: 113–118. 19.
Stone NN, Ratnow ER, Stock RG: Prior transurethral resection does not increase morbidity following real-time ultrasound-guided prostate seed implantation. Tech Urol 2000, 6: 123–127.
Partin AW, Mangold LA, Lamm DM, et al.: Contemporary update of prostate cancer staging nomograms (Partin tables) for the new millennium. Urology 2001, 58: 843–848.
Blasko JC, Grimm PD, Sylvester JE, et al.: The role of external beam radiotherapy with I-125/Pd-103 brachytherapy for prostate carcinoma. Radiother Oncol 2000, 57:273–278.
Ling CC: Permanent implants using Au-198, Pd-103 and 1–125: radiobiological considerations based on the linear quadratic model. Intl Radiat Oncol Biol Phys 1992, 23: 81–87.
Fowler J, Chappell R, Ritter M: Is alpha/beta for prostate tumors really low? Intl Radiat Oncol Biol Phys 2001, 50: 1021–1031.
Cha CM, Potters L, Ashley R, etal.: Isotope selection for patients undergoing prostate brachytherapy. IntJ Radiat Oncol Biol Phys 1999, 45: 391–395.
Lee LN, Stock RG, Stone NN: Role of hormonal therapy in the management of intermediate- to high-risk prostate cancer treated with permanent radioactive seed implantation. Intl Radiat Oncol Biol Phys 2002, 52: 444 452.
Sharkey J, Chovnick SD, Behar RJ, et al.: Minimally invasive treatment for localized adenocarcinoma of the prostate: review of 1048 patients treated with ultrasound-guided palladium-103 brachytherapy. J Endourol 2000, 14:343–350.
Stock RG, Stone NN, Tabert A, et al.: A dose-response study for 1–125 prostate implants. Intl Radiat Oncol Biol Phys 1998, 41:101–108.
Grimm PD, Blasko JC, Sylvester JE, et al.: 10-Year biochemical prostate-specific antigen control of prostate cancer with (125)1 brachytherapy. IntJ Radiat Oncol Biol Phys 2001, 51: 31–40.
Beyer DC, Brachman DG: Failure free survival following brachytherapy alone for prostate cancer: comparison with external beam radiotherapy. Radiother Oncol 2000, 57: 263–267.
Ragde H, Korb LJ, Elgamal AA, et al.: Modern prostate brachytherapy: prostate specific antigen results in 219 patients with up to 12 years of observed follow-up. Cancer2000, 89:135–141.
Grado GL, Larson TR, Balch CS, et al.: Actuarial disease-free survival after prostate cancer brachytherapy using interactive techniques with biplane ultrasound and fluoroscopic guidance. Intl Radiat Oncol Biol Phys 1998, 42:289–298.
Stock RG, Stone NN: The effect of prognostic factors on therapeutic outcome following transperineal prostate brachytherapy. Semin Surg Oncol 1997, 13: 454–460.
Zelefsky MJ, Hollister T, Raben A, etal.: Five-year biochemical outcome and toxicity with transperineal CT- planned permanent I-125 prostate implantation for patients with localized prostate cancer. Int J Radial Oncol Biol Phys 2000, 47: 1261–1266.
Critz FA, Williams WH, Levinson AK, et al.: Simultaneous irradiation for prostate cancer: intermediate results with modern techniques. J Urol2000, 164: 738–741.
Kestin LL, Martinez AA, Stromberg JS, etal.: Matched-pair analysis of conformal high-dose-rate brachytherapy boost versus external-beam radiation therapy alone for locally advanced prostate cancer. J Clin Oncol 2000, 18: 2869–2880.
Mate TP, Gottesman JE, Hatton J, etal.: High dose-rate afterloading 1922Iridium prostate brachytherapy: feasibility report. Intl Radiat Oncol Biol Phys 1998, 41: 525–533.
Galalae RM, Kovacs G, Schultze J, et al.: Long-term outcome after elective irradi¬ation of the pelvic lymphatics and local dose escalation using high-dose-rate brachytherapy for locally advanced prostate cancer. Intl Radiat Oncol Biol Phys 2002, 52: 81–90.
Mate TP, Gottesman JE, Hatton J, et al.: High dose-rate afterloading 192 Iridium prostate brachytherapy: feasibility report. Intl Radiat Oncol Biol Phys 1998, 41: 525–533.
Syed AM, Puthawala A, Sharma A, et al.: High-dose-rate brachytherapy in the treatment of carcinoma of the prostate. Cancer Control 2001, 8: 511–521.
Martinez AA, Pataki I, Edmundson G, et al.: Phase!! prospective study of the use of conformal high-dose-rate brachytherapy as monotherapy for the treatment of favorable stage prostate cancer: a feasibility report. Intl Radiat Oncol Biol Phys 2001, 49: 61–69.
Yoshioka Y, Nose T, Yoshida K, etal.: High-dose-rate interstitial brachytherapy as a monotherapy for localized prostate cancer: treatment description and preliminary results of a phase I/11 clinical trial. Int.) Radiat Oncol Biol Phys 2000, 48: 675–681.
Brenner DJ, Martinez A, Edmundson GK, et al.: Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha/beta ratio), similar to late-responding normal tissue. Intl Radiat Oncol Biol Phys 2002, 52: 6–13.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2003 Current Medicine, Inc.
About this chapter
Cite this chapter
Ritter, M.A. (2003). Permanent Seed Interstitial Prostate Brachytherapy. In: Bruskewitz, R.C. (eds) Atlas of the Prostate. Current Medicine Group, London. https://doi.org/10.1007/978-1-4615-6505-5_13
Download citation
DOI: https://doi.org/10.1007/978-1-4615-6505-5_13
Publisher Name: Current Medicine Group, London
Print ISBN: 978-1-4615-6507-9
Online ISBN: 978-1-4615-6505-5
eBook Packages: Springer Book Archive